Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years.

Autor: Kluberg SA; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. Electronic address: sheryl_kluberg@hphci.harvard.edu., Simon AL; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA., Alam SM; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA., Peters A; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA., Horgan C; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA., Li D; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA., Moyneur E; Statlog Inc., Quebec City, QC, Canada., Messenger-Jones E; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA., Platt R; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA., McMahill-Walraven CN; CVS Health, Blue Bell, PA, USA., Djibo DA; CVS Health, Blue Bell, PA, USA., Daniels K; Carelon Research, Wilmington, DE, USA., Jamal-Allial A; Carelon Research, Wilmington, DE, USA., Pernar CH; Optum, Boston, MA, USA., Ziyadeh NJ; Optum, Boston, MA, USA., Ma Q; Humana Healthcare Research, Louisville, KY, USA., Selvan M; Humana Healthcare Research, Louisville, KY, USA., Spence O; GSK, Rockville, MD, USA., Oraichi D; GSK, Rockville, MD, USA., Seifert H; GSK, Rockville, MD, USA., Franck V; GSK, Wavre, Belgium., Gamble S; GSK, Rockville, MD, USA., Yun H; GSK, Rockville, MD, USA.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2024 Oct; Vol. 68, pp. 152518. Date of Electronic Publication: 2024 Jul 14.
DOI: 10.1016/j.semarthrit.2024.152518
Abstrakt: Objective: To assess whether recombinant zoster vaccine (RZV) is associated with an increased risk of new-onset gout among US adults aged ≥50 years.
Methods: We conducted a real-world, retrospective safety study with a self-controlled risk interval (SCRI) design using administrative claims data. We included health plan members aged ≥50 years with RZV exposure, followed by incident gout within 60 days. Days 1-30 following RZV exposure were considered the risk window (RW), and days 31-60 were considered the control window (CW). We estimated the risk ratio (RR) of gout in the RW versus CW, using a conditional Poisson model. The primary analysis estimated the risk of incident gout following any RZV dose. Sensitivity analyses evaluated dose 1- and dose 2-specific risks, risk among patients compliant with recommended dose spacing of 60-183 days, adjustment for seasonality, and restriction to the pre-COVID-19 era (before December 1, 2019).
Results: A total of 461,323 individuals received ≥1 RZV dose; we included 302 individuals (mean age 72.5 years; 66 % male) with evidence of new-onset gout within 60 days in SCRI analyses. A total of 153 (50.7 %) individuals had gout events in the RW and 149 (49.3 %) in the CW (RR 1.03; 95 % confidence interval 0.81, 1.29). All sensitivity analyses had consistent results, with no association of RZV with incident gout.
Conclusion: In a population of US adults aged ≥50 years, there was no statistically significant increase in the risk of gout during the 30 days immediately after RZV exposure, compared with a subsequent 30-day CW.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. SAK, ALS, SA, AP, CH, DL, EM-J, RP, AJ-A, QM, and MS have no conflicts of interest to declare. EM has previously consulted for Pfizer. CNM-W and DAD are employees of, and stockholders in, CVS Health. KD has provided independent contracting for AbbVie/Abbott, AstraZeneca, GSK, and Pfizer. CHP and NJZ are employees of Optum and may own stock in UnitedHealth Group. OS, DO, HS, VF, SG, and HY are employees of, and shareholders in, GSK.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: